Helsinn completes Stability Centre at Irish drug manufacturing facility
Helsinn has opened a state-of-the-art Stability Centre at its Helsinn Birex Pharmaceuticals facility in Dublin, Ireland.
Helsinn has opened a state-of-the-art Stability Centre at its Helsinn Birex Pharmaceuticals facility in Dublin, Ireland.
The Swiss pharmaceutical group's new facility, which has a total storage capacity of 24m³, contains stability chambers that will operate at ICH conditions of 25°C/60% RH, 30°C/65% RH, and 40°C/75% RH. It also has a refrigerated chamber to store samples at 5°C and a freezer at -20°C.
The centre has the capacity to meet the Helsinn Group's foreseeable stability requirements for commercial and development products. It is also available as a service for third party clients.
"The completion of this new stability center at Helsinn Birex Pharmaceuticals provides an important addition to Helsinn's capability to monitor the quality of its product portfolio," said Padraig Somers, general manager.
'Additionally, it complements Helsinn's capabilities to optimise its product formulations during the development process."
To date Helsinn has invested more than Euro 55m in Ireland where it employs a total of 210 people at its four separate businesses - Helsinn Birex Pharmaceuticals, Helsinn Chemicals Ireland and a sales and marketing company, Helsinn Birex Therapeutics with its Ergha Healthcare division.
Helsinn's expertise is in the in-licensing of late-stage pharmaceutical compounds in therapeutic niche areas including oncology supportive care, anti-inflammatory and gastrointestinal treatments.